A Turkish Gynecologic Oncology Group study of fertility-sparing treatment for early-stage endometrial cancer

Simple item page
dc.contributor.authorDursun P.
dc.contributor.authorErkanli S.
dc.contributor.authorGüzel A.B.
dc.contributor.authorGultekin M.
dc.contributor.authorTarhan N.C.
dc.contributor.authorAltundag O.
dc.contributor.authorDemirkiran F.
dc.contributor.authorBeşe T.
dc.contributor.authorYildirim Y.
dc.contributor.authorBozdag G.
dc.contributor.authorYarali H.
dc.contributor.authorSimsek T.
dc.contributor.authorOzcelik B.
dc.contributor.authorOrtaç F.
dc.contributor.authorTaskin S.
dc.contributor.authorGuvenal T.
dc.contributor.authorOzgul N.
dc.contributor.authorHaberal A.
dc.contributor.authorVardar M.A.
dc.contributor.authorDede M.
dc.contributor.authorYenen M.
dc.contributor.authorAltintas A.
dc.contributor.authorArvas M.
dc.contributor.authorAyhan A.
dc.date.accessioned2025-04-10T11:15:00Z
dc.date.available2025-04-10T11:15:00Z
dc.date.issued2012
dc.description.abstractObjective: To analyze the results of fertility-sparing treatment of early-stage endometrial cancer (EC) in patients treated at Turkish gynecologic oncology centers, and to present a review of the literature. Methods: Thirteen healthcare centers in Turkey were contacted to determine if they were eligible to participate in the study. Centers that were eligible and agreed to participate were sent a database form to record the demographic characteristics, clinicopathologic findings, and follow-up results for their EC patients. Results: Eleven Turkish healthcare centers provided data on 43 EC patients. Mean duration of treatment was 5 months and mean follow-up was 49 months. In total, 35 (81.4%) patients were tumor free following primary progesterone therapy. Mean time from the end of progesterone therapy to pregnancy was 10.6 ± 4.3 months (range, 3-18 months). Two patients had tumor recurrence during follow-up. The pregnancy rate among the 31 women who actively sought pregnancy was 41.9% (n = 13). Conclusion: Conservative management of early-stage EC in women of reproductive age using oral progestins was effective and did not compromise oncological outcome. Pregnancy in the study patients was achieved spontaneously and artificially. © 2012 International Federation of Gynecology and Obstetrics.
dc.identifier.DOI-ID10.1016/j.ijgo.2012.06.010
dc.identifier.urihttp://hdl.handle.net/20.500.14701/50671
dc.publisherJohn Wiley and Sons Ltd
dc.titleA Turkish Gynecologic Oncology Group study of fertility-sparing treatment for early-stage endometrial cancer
dc.typeConference paper

Files

Collections

Scopus Koleksiyonu